Rebif

Bayer AG's Betaseron, and Rebif, which is marketed by Pfizer Inc. and Germany's Merck KGaA.

Drug Seeks to Fix MS Damage 2009

Merck's confidence in 2011 may in part be due to strong fourth-quarter sales of its key multiple-sclerosis product Rebif, Mr. Frericks said.

Germany's Merck Posts 73% Gain in Net Profit Natascha Divac 2011

Biogen's Avonex also had more than $2 billion in annual revenue, while Bayer's Betaseron and Merck's Rebif had more than $1 billion in sales.

Novartis Wins European Backing for MS Pill Goran Mijuk 2011

Biogen's Avonex also had more than $2 billion in annual revenue, while Bayer AG's Betaseron and Merck's Rebif had more than $1 billion in sales.

Novartis's MS Drug Gets Approval from EU Goran Mijuk 2011

The risk of relapse dropped from an average of two relapses every three years using other approved MS drugs such as Copaxone, Rebif, Betaseron, and Avonex—all of which reduce flare-ups or minimize the appearance of lesions in the brain—to one every three years with Tysabri.

The Autoimmune Epidemic Donna Jackson Nakazawa 2008

The risk of relapse dropped from an average of two relapses every three years using other approved MS drugs such as Copaxone, Rebif, Betaseron, and Avonex—all of which reduce flare-ups or minimize the appearance of lesions in the brain—to one every three years with Tysabri.

The Autoimmune Epidemic Donna Jackson Nakazawa 2008

The multiple sclerosis drugs Avonex, Rebif, and Betaseron can lead to rare liver problems, Copaxone can lead to severe allergic reaction.

The Autoimmune Epidemic Donna Jackson Nakazawa 2008

The multiple sclerosis drugs Avonex, Rebif, and Betaseron can lead to rare liver problems, Copaxone can lead to severe allergic reaction.

The Autoimmune Epidemic Donna Jackson Nakazawa 2008

Serono's top-selling multiple sclerosis treatment, Rebif, has cushioned Merck against regulatory setbacks for some late-stage drugs and slowing growth at its chemicals business, a supplier for the mature liquid-crystal-display industry.

Merck KGaA's Bet on Millipore's Petri-Dish Magic Matthew Curtin 2010

The entire Serono business has an Ebitda margin of around 20%, with much of that the result of its flagship MS drug Rebif.

Commerzbank's Conundrum 2010